about
Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate-high cardiovascular risk.Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.Familial hypercholesterolemia in childhood and adolescents: A hidden reality.Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease.Serum palmitoleate acts as a lipokine in subjects at high cardiometabolic risk.FABP4 plasma concentrations are determined by acquired metabolic derangements rather than genetic determinants.Negative effect of a low-carbohydrate, high-protein, high-fat diet on small peripheral artery reactivity in patients with increased cardiovascular risk.Even low physical activity levels improve vascular function in overweight and obese postmenopausal women.Low-carbohydrate, high-protein, high-fat diet alters small peripheral artery reactivity in metabolic syndrome patients.APOA5 genetic and epigenetic variability jointly regulate circulating triacylglycerol levels.How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?Impact of epidermal fatty acid binding protein on 2D-NMR-assessed atherogenic dyslipidemia and related disorders.Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders.Physical activity below the minimum international recommendations improves oxidative stress, ADMA levels, resting heart rate and small artery endothelial function.Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular riskMaximum Low-density Lipoprotein Cholesterol Lowering Capacity Achievable With Drug Combinations. When 50 Plus 20 Equals 60Novel mutations in the GPIHBP1 gene identified in 2 patients with recurrent acute pancreatitisPrevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception
P50
Q34415967-EF6B4DA0-0346-40A1-B45F-3C671963A7DFQ37150845-8F7DE550-5B4A-4688-9168-B2D629CCE08BQ38846416-C1379952-D5BD-4E38-8AF3-F328C61AFF93Q39249394-1B7DA860-EA18-4C4B-8CD0-77E2055CD05EQ40052884-45534137-A60B-4005-9964-2FF89C37D1BBQ40769629-17C9ED6B-5ABD-4587-A4C4-729DC588BDA9Q43601442-52312F5B-5FB7-4DEF-819F-F1A409A8BA69Q44553748-952B72E4-E00E-475B-A6A1-268D7815FDACQ44864546-6B940F33-8038-471C-BEA6-215195E8897CQ49055752-B1669141-68B6-485B-B841-A042A5A7F142Q50631425-67FBE5CA-0608-48BA-A0A3-105D829278C6Q51385354-5354906D-5F57-4698-938F-B693E9A80930Q51571152-E615C7FF-6669-4F24-ACA3-84A07BEEC0CFQ53085754-620C82AD-FE08-4020-9B2B-C11A62E5174BQ61409365-B6C8A095-63D6-451E-AB1F-9928DA74FFCAQ87250868-F469E5E3-B3BD-4B34-BBB0-932DBE8B12BDQ87320688-3AE6D9C4-39D1-4B99-A8C5-DE03FEA3CB4FQ88084558-A9E83607-79C2-4A19-86DE-BE01D1FCAFF5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daiana Ibarretxe
@ast
Daiana Ibarretxe
@en
Daiana Ibarretxe
@es
Daiana Ibarretxe
@nl
Daiana Ibarretxe
@sl
type
label
Daiana Ibarretxe
@ast
Daiana Ibarretxe
@en
Daiana Ibarretxe
@es
Daiana Ibarretxe
@nl
Daiana Ibarretxe
@sl
prefLabel
Daiana Ibarretxe
@ast
Daiana Ibarretxe
@en
Daiana Ibarretxe
@es
Daiana Ibarretxe
@nl
Daiana Ibarretxe
@sl
P106
P31
P496
0000-0002-5442-1930